Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Preora Diagnostics Inc.

Noninvasive lung cancer detection

This article was originally published in Start Up

Executive Summary

Just as the PAP smear has drastically reduced the incidence and number of deaths from cervical cancer over the decades, Preora Diagnostics Inc. expects its low-cost test to be an effective prescreening tool for lung cancer, in the convenience of a primary-care setting. The start-up believes its test will be able to identify asymptomatic stage 1 and stage 2 cancers.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT038053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel